Best practice in cannabinoid-based R&D

Webinar: How to lower the risk of failure and increase the odds for scientific success

Cannabinoids, such as cannabidiol, hold great therapeutic promise. However, currently available drug delivery formats, as well as ongoing R&D, face challenges with regard to API absorption and patient compliance. In this webinar we share learnings from an in-depth technology assessment for improving the bioavailability of CBD while enabling patient-friendly formats with high API loading.

Speakers:

  • Zdravka Misic - Innovation Project Manager, dsm-firmenich
  • Christiane Schweiggert - Senior Scientist in Formulation & Materials Science, dsm-firmenich
hmo webinar screengrab
Related content
Related articles
  • New CBD bioavailability study with CBtru®

    New CBD bioavailability study with CBtru®

    New study confirms CBtru®, a novel CBD drug product intermediate, demonstrates equal bioavailability to leading oil-based CBD drug product.

  • Synthetic vs natural CBD ingredients: The differences and why they matter

    Synthetic vs natural CBD ingredients: The differences and why they matter

    Explore five differences between synthetic and natural CBD APIs to inform your next research and development project.

  • From patient trust to emerging evidence: Expert insights behind CBD and chronic pain management

    From patient trust to emerging evidence: Expert insights behind CBD and chronic pain management

    Explore the latest research on CBD and pain relief, including highlights from patient insights, pre-clinical and clinical studies.

How can we help you?

  • New product concept

    Got a notion for your next project or breakthrough innovation? Let’s put our heads together.

  • Sample request

    Don’t just take our word for it. Discover how our solutions can support your product development journey. 

  • Quote request

    Tell us about your project needs. We’ll build you a tailored quote.